Results 11 to 20 of about 14,613 (227)
Flecainide in clinical practice [PDF]
Cardiology Journal, 2023 Flecainide, similar to encainide and propafenone, is IC class antiarrhythmic, inhibiting Nav1.5 sodium channels in heart muscle cells and modulates cardiac conduction. Despite its over 40-year presence in clinical practice, strong evidence and well-known
Mikołaj Basza +14 more
doaj +5 more sources
How does flecainide impact RyR2 channel function? [PDF]
The Journal of General Physiology, 2022 The promiscuity of flecainide underscores its antiarrhythmic efficacy in CPVT: this paper presents a discussion of its mechanisms of action on the cardiac ryanodine receptor (RyR2) and other cardiac excitation–contraction coupling proteins.
S. Salvage +3 more
semanticscholar +3 more sources
The Antiarrhythmic Mechanisms of Flecainide in Catecholaminergic Polymorphic Ventricular Tachycardia
Frontiers in Physiology, 2022 Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a severe yet rare inherited arrhythmia disorder. The cornerstone of CPVT medical therapy is the use of β-blockers; 30% of patients with CPVT do not respond well to optimal β-blocker ...
Yukun Li +17 more
doaj +2 more sources
Flecainide Toxicity Secondary to Accidental Overdose: A Pediatric Case Report of Two Brothers
Case Reports in Critical Care, 2021 Flecainide is a class 1C antiarrhythmic with a narrow therapeutic window and thereby a high-risk medication for causing acute toxicity. Dysrhythmias secondary to flecainide ingestion are often refractory to antiarrhythmics and cardioversion, and patients
Sarah E. Gardner Yelton +4 more
doaj +2 more sources
Neonatal Near Fatal Flecainide Toxicity
Saudi Journal of Emergency MedicineBackground: Flecainide is an anti-arrhythmic medication with a narrow therapeutic index and a high mortality rate, when overdosed. Few cases of flecainide toxicity in neonates and children due to medication error have been reported in the literature.
Fatma Mohammed Abdullah Al Balushi +5 more
doaj +2 more sources
Flecainide Toxicity Leading to Loss of Pacemaker Capture and Cardiac Arrest
JACC: Case Reports, 2021 An 86-year-old man with paroxysmal atrial fibrillation on flecainide, a class IC antiarrhythmic, presented with cardiac arrest. The patient had extremely wide QRS complexes with inconsistent pacemaker capture on electrocardiography.
Harold Rivner, MD +1 more
doaj +2 more sources
Flecainide-Associated Cardiogenic Shock in a Patient with Atrial Fibrillation
Case Reports in Cardiology, 2019 Flecainide is a frequently used antiarrhythmic drug, recommended by current guidelines as a first-line treatment option for restoring and maintaining sinus rhythm in patients with atrial fibrillation and no significant structural heart disease.
Erind Gjermeni +3 more
doaj +2 more sources
Ranolazine as an Alternative Therapy to Flecainide for SCN5A V411M Long QT Syndrome Type 3 Patients
Frontiers in Pharmacology, 2020 The prolongation of the QT interval represents the main feature of the long QT syndrome (LQTS), a life-threatening genetic disease. The heterozygous SCN5A V411M mutation of the human sodium channel leads to a LQTS type 3 with severe proarrhythmic effects
Jordi Cano +10 more
doaj +2 more sources
Therapeutic Advances in Cardiovascular Disease, 2020 Introduction: Current atrial fibrillation (AF) guidelines recommend flecainide as a first-line rhythm control option in patients without structural heart disease. While there is proven efficacy in clinical trials and guideline support, it is hypothesized
Mikayla Muzzey +4 more
doaj +2 more sources
Flecainide toxicity—Clinical diagnosis and management of an urgent condition
Clinical Case ReportsKey Clinical Message Clinical suspicion, clinical presentation, and electrocardiogram can help clinicians diagnose flecainide toxicity. Currently, there are no guidelines for the management of patients with flecainide toxicity.
George Bazoukis +13 more
doaj +2 more sources